Abstracts tagged "Eye disease"

Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Ohoud AlAhmed¹, Amanda Way ², Shoghik akoghlanian ², Fatima Barbar-Smiley ², Stephanie Lemle ², Darby MacDonald ², Kelly Wise ², Stacy Ardoin ² and Vidya Sivaraman ³, ¹Nationwide Children's Hospital, Columbu, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
Abstract Number: 1807 • 2019 ACR/ARP Annual Meeting
Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease
George J. Kahaly ¹, Saba Sile ², Elizabeth H.Z. Thompson ², Thomas Vescio ³, Renee Perdok ³, Jeffrey W. Sherman³, Terry J. Smith ⁴ and Raymond S. Douglas ⁵, ¹Johannes Gutenberg University Medical Center, Mainz, Germany, ²Horizon Therapeutics plc, Brisbane, CA, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴University of Michigan Kellogg Eye Center, Ann Arbor, MI, ⁵Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Thyroid eye disease (TED) is a debilitating autoimmune disorder characterized by inflammation and exophthalmia along with significantly altered appearance and vision changes. TED is…
Abstract Number: 2156 • 2019 ACR/ARP Annual Meeting
Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome
Qingping Yao¹ and Apostolos Kontzias ¹, ¹Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321), formerly termed nucleotide-binding, oligomerization domain 2(NOD2)-associated autoinflammatory disease, has become increasingly recognized. The disease has been reported in America,…
Abstract Number: 2656 • 2019 ACR/ARP Annual Meeting
The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy
Sarah Chung¹, Meredith Morcos ², Scott Pollock ¹ and Bernard Ng ³, ¹University of Washington Division of Rheumatology, Seattle, WA, ²University of Washington Division of Rheumatology, Seattle, ³University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle, WA
Background/Purpose: This study aimed to identify the incidence of ophthalmic complication of giant cell arteritis (GCA) among subjects with negative temporal artery biopsy (TAB) and to…
Abstract Number: 2179 • 2018 ACR/ARHP Annual Meeting
Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study
Ksenia Gukova¹, John M. Esdaile², Hamid Tavakoli³ and J. Antonio Avina-Zubieta^1,2, ¹Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Antimalarial drugs (AM) are commonly used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). AM can be associated with retinal toxicity that…
Abstract Number: 2635 • 2017 ACR/ARHP Annual Meeting
Dosechecker: Solving the Hydroxychloroquine Dosing Dilemma with a Smart Phone App
Elliot Perlman¹, Robert Friday², Paul Greenberg³, David Browning⁴ and Joan Miller⁵, ¹Rhode Island Eye Institute, Providence, RI, ²Division of Rheumatology, Department of Medicine, Newton-Wellesley Hospital, Newton, MA, ³Division of Ophthalmology, Alpert Medical School, Brown University, Providence, RI, ⁴Charlotte Eye Ear, Nose, and Throat Associates, Charlotte, NC, ⁵Department of Ophthalmology, Harvard Medical School and Massachusetts Eye and Ear Institute, Boston, MA
Background/Purpose: Hydroxychloroquine retinopathy (HCR) is a potentially blinding but largely preventable disease. The true prevalence of HCR is unknown among the 350,000 Americans who take…
Abstract Number: 436 • 2016 ACR/ARHP Annual Meeting
Are Providers Recommending Appropriate Screening for Hydroxychloroquine-Induced Retinal Toxicity to Their Patients?
Sarah Haserodt¹, Chris Tonner², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Although well tolerated by most patients, hydroxychloroquine (HCQ) can cause irreversible retinal damage. The American Association of Ophthalmology (AAO) 2016 Guidelines recommend a baseline…
Abstract Number: 1562 • 2015 ACR/ARHP Annual Meeting
Clinical Correlates, Outcomes and Predictors of Episcleritis and Scleritis Associated with Rheumatoid Arthritis
Cristian Caimmi¹, Wendy M. Smith², Cynthia S. Crowson³, Eric L. Matteson⁴ and Ashima Makol⁵, ¹Unit of Rheumatology, Department of Medicine,, University of Verona, Verona, Italy, ²Department of Ophthalmology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Inflammatory ocular disease (IOD) has traditionally been regarded as a severe extra-articular manifestation of rheumatoid arthritis (RA) with high mortality. This study aims to…
Abstract Number: 892 • 2015 ACR/ARHP Annual Meeting
Autoimmune Associated Orbital Inflammatory Masses and Response to Immunosuppressive Therapy
Alina Casian¹, Shirish Sangle (joint first author)², Ritu Malaiya³, Pamela Lutalo⁴, Louise Nel⁵, Bina Menon⁶, Hema Varma⁷, Miles Stanford⁸ and David P. D'Cruz⁵, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, UK, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ⁴Rheumatology, St. George's Hospital, London, United Kingdom, ⁵Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁶Rheumatology, Guy's Hospital, London, United Kingdom, ⁷Radiology, Guy's and St. Thomas' Hospital, London, United Kingdom, ⁸Ophthalmology, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: To characterize a single centre retrospective case series of patients with orbital inflammatory masses associated with autoimmune diseases including granulomatosis with polyangiitis(GPA)(formerly Wegener’s granulomatosis),…
Abstract Number: 1390 • 2015 ACR/ARHP Annual Meeting
Hidradenitis Suppuritiva Is Associated with Inflammatory Eye Disease
Abrahim U. Syed¹, Didem Uzunaslan², Careen Y. Lowder³, Sunil Srivastava³, Juan J. Maya¹ and Rula A Hajj-Ali⁴, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cole Eye Institute, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Hidradenitis Suppurativa (HS) is an inflammatory skin condition that can cause profound morbidity. Patients can present with recurrent nodules, sinus tract formation, abscesses and/or…
Abstract Number: 1327 • 2014 ACR/ARHP Annual Meeting
Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis
Melissa R. Bussey¹, Gabrielle A. Morgan², Maria C. Amoruso², Bahram Rahmani³ and Lauren M. Pachman⁴, ¹Rheumatology, Division of Rheumatology, Loyola University Medical Center, Maywood, IL, ²Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Cure JM Myositis Center, Chicago, IL, ³Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Orbital myositis (OM), an inflammatory disease affecting the extra-ocular muscles, typically presents in the third decade. It more commonly affects females and is extremely…
Abstract Number: 199 • 2013 ACR/ARHP Annual Meeting
Overcoming The Barriers To Adequate Hydroxychloroquine Retinal Toxicity Screening
Cristina Arriens¹ and Elizabeth Blair Solow², ¹Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ²Rheumatology, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is considered a minimal risk drug in the treatment arsenal for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other rheumatic diseases;…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].